[go: up one dir, main page]

WO2009029762A3 - Farnésylamines en tant qu'inhibiteurs du cycle visuel - Google Patents

Farnésylamines en tant qu'inhibiteurs du cycle visuel Download PDF

Info

Publication number
WO2009029762A3
WO2009029762A3 PCT/US2008/074743 US2008074743W WO2009029762A3 WO 2009029762 A3 WO2009029762 A3 WO 2009029762A3 US 2008074743 W US2008074743 W US 2008074743W WO 2009029762 A3 WO2009029762 A3 WO 2009029762A3
Authority
WO
WIPO (PCT)
Prior art keywords
visual cycle
farnesylamine
inhibitors
drug
visual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/074743
Other languages
English (en)
Other versions
WO2009029762A2 (fr
Inventor
Robert R Rando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of WO2009029762A2 publication Critical patent/WO2009029762A2/fr
Publication of WO2009029762A3 publication Critical patent/WO2009029762A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Selon l'invention, un médicament peut être utilisé dans la préparation d'une substance médicamenteuse pour le traitement ou la prévention d'un trouble ophtalmologique, ce médicament inhibant ou antagonisant le cycle visuel à une étape du cycle visuel qui intervient à l'extérieur d'un disque d'une cellule photoréceptrice de type bâtonnet.
PCT/US2008/074743 2007-08-31 2008-08-29 Farnésylamines en tant qu'inhibiteurs du cycle visuel Ceased WO2009029762A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96928907P 2007-08-31 2007-08-31
US60/969,289 2007-08-31

Publications (2)

Publication Number Publication Date
WO2009029762A2 WO2009029762A2 (fr) 2009-03-05
WO2009029762A3 true WO2009029762A3 (fr) 2009-04-23

Family

ID=40388126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/074743 Ceased WO2009029762A2 (fr) 2007-08-31 2008-08-29 Farnésylamines en tant qu'inhibiteurs du cycle visuel

Country Status (1)

Country Link
WO (1) WO2009029762A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2783699C (fr) 2009-12-08 2019-01-15 Case Western Reserve University Composes d'amines primaires destines au traitement de troubles oculaires

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510510A (en) * 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US20060069078A1 (en) * 2004-02-17 2006-03-30 Rando Robert R Management of ophthalmologic disorders, including macular degeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510510A (en) * 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US20060069078A1 (en) * 2004-02-17 2006-03-30 Rando Robert R Management of ophthalmologic disorders, including macular degeneration

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOLCZAK M. ET AL.: "Positively charged retinoids are potent and selective inhibitors of the trans- cis isomerization in the retinoid (visual) cycle.", PROC NATL ACAD SCI U S A., vol. 102, no. 23, 7 June 2005 (2005-06-07), pages 8162 - 7, XP008107477, DOI: doi:10.1073/pnas.0503318102 *
GOLLAPALLI DR ET AL.: "The specific binding of retinoic acid to RPE65 and approaches to the treatment of macular degeneration.", PROC NATL ACAD SCI U S A., vol. 101, no. 27, 6 July 2004 (2004-07-06), pages 10030 - 5, XP003023101, DOI: doi:10.1073/pnas.0401936101 *
MAEDA A ET AL.: "Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice.", MOL PHARMACOL., vol. 4, October 2006 (2006-10-01), pages 1220 - 9, XP002680489, DOI: doi:10.1124/MOL.106.026823 *

Also Published As

Publication number Publication date
WO2009029762A2 (fr) 2009-03-05

Similar Documents

Publication Publication Date Title
WO2005079774A3 (fr) Gestion de troubles ophtalmologiques, notamment la degenerescence maculaire
WO2007019503A3 (fr) Gestion de troubles ophtalmologiques tels que la degenerescence maculaire
PH12017500930A1 (en) Hsp90 inhibitor combinations
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
WO2009129486A3 (fr) Essais d'évaluation de thérapie à programmer
WO2012083017A3 (fr) Formes posologiques pour des médicaments médiocrement solubles administrés par voie orale à libération contrôlée et leurs utilisations
WO2007146426A3 (fr) Nanobilles pour délivrance de médicament
HK1223319A1 (zh) 用於治疗或预防眼科病的方法
PT2364983E (pt) Novo derivado tricíclico ou seus sais farmaceuticamente aceitáveis, seu método de preparação, e composição farmacêutica que o contém
ZA201005905B (en) Methods,dosage forms,and kits for administering ziprasidone without food
WO2009142731A3 (fr) Thérapie combinée associant niacine et anti-inflammatoire non stéroïdien (nsaid)
WO2007084857A3 (fr) Procédés et compositions de traitement de troubles prolifératifs cellulaires
BRPI0916102A2 (pt) "método para a prevenção da hérnia paraestomal, método para preparar uma hérnia paraestomal e dispositivo para preparar ou reduzir a incidência da hérnia paraestomal"
WO2012100043A3 (fr) Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
WO2011108826A3 (fr) Formulation complexe pour administration orale comprenant une formulation probiotique et un agoniste du récepteur 5-ht4, et procédé de préparation associé
WO2009149056A3 (fr) Combinaisons de niacine et d'un oxicame
WO2012158672A3 (fr) Composés utilisés dans le traitement de la mucosite
EP2012807A4 (fr) Composition pharmaceutique d'entérosorbant et de prébiotiques, formes galéniques et procédé pour la prévention et le traitement de troubles gastrointestinaux
WO2009144551A3 (fr) Utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d’un médicament permettant la régulation du niveau de potassium dans le sang
WO2010148314A3 (fr) Préparation d'ésoméprazole et de ses sels pharmaceutiquement acceptables
CL2013001684A1 (es) Composicion farmaceutica de administracion oral que comprende alisporivir, un componente lipofilico, un tensoactivo y un componente hidrofilico.
WO2010120817A3 (fr) Dispositif à nanocanaux et procédés apparentés
WO2007132379A3 (fr) Dispositif d'administration de médicaments et/ou de surveillance de l'état d'un patient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08798936

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08798936

Country of ref document: EP

Kind code of ref document: A2